Our latest news.

March 24, 2021

On Target Laboratories Secures $21 Million for Development and Commercialization of Pafolacianine Sodium Injection

Read More
March 3, 2021

On Target Laboratories Announces U.S. FDA Acceptance and Priority Review of New Drug Application for pafolacianine sodium injection for Identification of Ovarian Cancer During Surgery

Read More
December 3, 2020

On Target Laboratories Announces the Appointment of Tommy Lee as Vice President, Clinical Operations

Read More
October 1, 2020

On Target Laboratories Announces the Appointment of Patrick Spangler as Chief Financial Officer

Read More
July 8, 2020

First Patient Enrolled in the Phase 3 ELUCIDATE Trial of Pafolacianine Sodium (formerly OTL38) in the Intraoperative Identification of Lung Cancer Lesions

Read More
January 27, 2020

Intraoperative Molecular Imaging of Non-Small Cell Lung Cancer Improves Outcomes for 26 Percent of Patients in Multi-Institutional Phase 2 Clinical Trial

Read More
October 15, 2019

Positive Phase 2 Study Results Published for On Target's Intraoperative Cancer Imaging Agent.

Read More
August 19, 2019

On Target Completes OTL38 Phase 2 Clinical Trial in Lung Cancer

Read More
August 12, 2019

On Target Laboratories Appoints Chief Executive Officer

Read More
October 15, 2018

On Target Laboratories Announces Publication Supporting Use of OTL78 to Highlight Prostate Cancer Lesions

Read More
November 3, 2017

On Target Laboratories Raises Additional Capital from H.I.G. BioHealth Partners, Elevate Ventures and Helsinn

Read More
Brand Strategy By Assembly
Developed By Alchemy + Aim